Quanterix Corporation has announced the commercial launch of two groundbreaking phospho-tau assays, p-Tau 205 and p-Tau 212, representing the first-to-market availability of these blood-based biomarkers for Alzheimer's disease and neurodegeneration research. The announcement coincides with the company's prominent presence at the Alzheimer's Association International Conference (AAIC) 2025, where more than 55 posters and presentations featured data generated using its Simoa® technology.
Novel Biomarker Detection Capabilities
The newly launched assays enable precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa® platform, the p-Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers.
"The addition of p-Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's," said Masoud Toloue, PhD, CEO of Quanterix.
Enhanced Platform Integration
Quanterix's capabilities have been significantly expanded through its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue.
The integration creates a powerful combination of tissue- and fluid-based biomarker discovery platforms designed to accelerate translation from bench to bedside. "Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context," Toloue explained.
Commercial Availability and Applications
The p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments, or through testing directly via Quanterix's in-house Accelerator Lab. The facility is CLIA-licensed and ISO 15189-accredited, providing contract biomarker testing services to global partners in pharmaceutical, biotechnology, and academic sectors.
Company Portfolio and Impact
Quanterix has established itself as a global leader in ultra-sensitive biomarker detection, with its proprietary Simoa® technology delivering industry-leading sensitivity for detecting and quantifying biomarkers in blood and other fluids at concentrations far below traditional limits. The company has supported more than 3,400 peer-reviewed publications over nearly two decades of operation.
The 2025 acquisition of Akoya Biosciences added multiplexed tissue imaging with single-cell resolution to Quanterix's portfolio, along with 1,396 installed instruments. The combined company now offers an integrated platform connecting biology across blood and tissue, advancing precision medicine from discovery to diagnostics across neurology, oncology, and immunology applications.
